Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Promega GloResponse™ Luciferase Reporter Cell Lines

Prebuilt, optimized luciferase reporter cell lines allow for the rapid development of a reporter assay based on the pathway of interest regulating the luciferase gene

Manufacturer:  Promega E8530

 View more versions of this product

Catalog No. PRE8530

This item has been discontinued by the manufacturer and is no longer available. Please call customer service for assistance: 1-800-766-7000.



The GloResponse Cell Lines were generated by clonal selection of HEK293 cells stably transfected with pGL4-based vectors carrying specific response elements for the pathway of interest. The destabilized luc2P luciferase reporter is used for improved responsiveness to transcriptional dynamics. The luc2P gene is codon optimized for enhanced expression in mammalian cells, and the pGL4 plasmid backbone was engineered to reduce background reporter expression. The result is a cell line with very high induction levels when the pathway of interest is activated.

  • The GloResponse CRE-luc2P HEK293 Cell Line can be used to study and configure screening assays for Gs- and Gi/o-coupled GPCRs, which signal through cAMP and the cAMP Response Element (CRE)
  • The GloResponse NFAT-RE-luc2P HEK293 Cell Line should be used for Gq-coupled GPCRs, which signal through calcium ion release and activate the Nuclear Factor of Activated T-cells response element (NFAT-RE)
  • The GloResponse NF-κB-RE-luc2P HEK293 Cell Line is designed for rapid and convenient analysis of any cellular response that results in modulation of NF-κB activities
  • The GloResponse 9XGAL4UAS-luc2P HEK293 Cell Line contains nine repeats of GAL4UAS (Upstream Activator Sequence) driving the transcription of the luciferase reporter gene luc2P in response to binding of a fusion protein containing the GAL4 DNA Binding Domain and making the cell line suitable for the study of nuclear receptors or for the study other types of protein:protein and protein:DNA interactions (the GAL4 DNA Binding Domain partner must be introduced to this cell line by transfection or other similar techniques)



Human Embryonic Kidney 293 Cells
9XGAL4UAS-luc2P HEK293 Cell Line
For rapid development of a reporter assay based on the pathway of interest regulating the luciferase gene
2 × 1006 Cells
Product Certifications


Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

By use of this product, researcher agrees to be bound by the terms of this limited use statement. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.
Researchers may use this product for research use only, no commercial use is allowed. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that Researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, Researchers must either: (1) use luminescent assay reagents purchased from Promega Corporation for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. Promega makes no representations or warranties of any kind, either expressed or implied, including for merchantability or fitness for a particular purpose with regards to the product. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA. The above license relates to Promega patents and/or patent applications on improvements to the luciferase gene.
U.S. Patent 5,670,356.
Australian Patent 2003272419 and other patents pending.
Commercial use of this cell line requires a license from AdVec Inc.
HEK293 cells were obtained under license from AdVec Inc.
The method of recombinant expression of Coleoptera luciferase is covered by U.S. Patents 5,583,024; 5,674,713 and 5,700,673. A license (from Promega for research reagent products and from The Regents of the University of California for all other fields) is needed for any commercial sale of nucleic acid contained within or derived from this product.
Australian Patent 2001 285278 and other patents pending.
Mfr. No. E8510: The NFAT response element and its use are licensed under one or more of the following patents: U.S. Patents 5,837,840; 6,197,925; 5,989,810; 6,096,515; 6,388,052; 6,150,099; 6,171,781; 6,352,830; 6,312,899 and 6,875,571.